EXICURE, INC. Increase (Decrease) in Deferred Revenue
EXICURE, INC. (XCUR) reported Increase (Decrease) in Deferred Revenue of $0 for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-06
- EXICURE, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was $0.00.
- EXICURE, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was $0.00.
- EXICURE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$2.07M, a 122.22% decline year-over-year.
- EXICURE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$2.16M.
- EXICURE, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$8.28M, a 188.89% decline from fiscal 2016.
- EXICURE, INC. increase (decrease) in deferred revenue for fiscal 2016 was $9.31M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | -$2.07M derived: sum of 3 quarters · filed 2018-08-06 | -$4.22M derived: sum of 4 quarters · filed 2018-08-06 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 | -$2.07M derived: sum of 2 quarters · filed 2018-05-15 | -$4.22M derived: sum of 3 quarters · filed 2018-05-15 | -$6.29M derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-12-31 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$4.22M derived: sum of 2 quarters · filed 2018-03-09 | -$6.29M derived: sum of 3 quarters · filed 2018-08-06 | -$8.28M 10-K · filed 2018-03-09 |
| 2017-09-30 | -$2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$4.22M derived: sum of 2 quarters · filed 2018-08-06 | -$6.21M 10-Q · filed 2017-11-14 | $3.10M derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-06-30 | -$2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$4.05M 10-Q · filed 2018-08-06 | $5.26M derived: sum of 3 quarters · filed 2018-08-06 | |
| 2017-03-31 | -$1.98M 10-Q · filed 2018-05-15 | $7.33M derived: sum of 2 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $9.31M 10-K · filed 2018-03-09 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |